SecBot SecBot
8-K ·Filed Jun 3, 2026

NAMSW

NewAmsterdam Pharma Co N.V.
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago SEC0001193125-26-254615
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading catalyst. The ESPP is a standard employee benefit with minimal near-term dilution. Monitor for future ESPP purchase periods and any subsequent share issuances.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.90
T+0 close · Jun 3, 2026 · via day close
Latest settled
−33.68%
T+60 · $16.51
Vs SPY
−36.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $24.90entry
  2. T+1 · 6mo ago −14.40%α −14.80% · $21.31
  3. T+5 · 5mo ago −27.74%α −23.92% · $17.99
  4. T+20 · 5mo ago −5.84%α −4.84% · $23.44
  5. T+60 · 3mo ago −33.68%α −36.18% · $16.51

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where shareholders approved the adoption of the 2026 Employee Stock Purchase Plan (ESPP), the re-appointment of two non-executive directors, and the extension of authorization to issue ordinary shares and limit pre-emption rights. The ESPP authorizes the issuance of up to 1,150,000 ordinary shares at a 15% discount to the lower of the market price at the beginning or end of each six-month purchase period. This is a routine governance filing with no material financial impact.

Key Facts

  • Shareholders approved the 2026 Employee Stock Purchase Plan, authorizing up to 1,150,000 ordinary shares for issuance.
  • ESPP allows eligible employees to purchase shares at a 15% discount to the lower of the market price at the start or end of each six-month purchase period.
  • Shareholders approved the extension of authorization for the Board to issue ordinary shares (or rights) for a five-year period ending June 2, 2031.
  • Shareholders approved the extension of authorization for the Board to limit or exclude pre-emption rights for a five-year period ending June 2, 2031.
  • John W. Smither and Janneke van der Kamp were re-appointed as non-executive directors, each to serve until the 2030 annual general meeting.
  • A quorum of 91,538,612 ordinary shares (approximately 78.3%) voted at the meeting.
  • Proposal 6 (authorization to issue shares) passed with 59,539,558 votes for and 26,801,646 against.
  • Proposal 7 (authorization to limit pre-emption rights) passed with 57,890,766 votes for and 28,450,917 against.
  • Proposal 8 (ESPP approval) passed with 86,221,442 votes for and 139,927 against.

Financial Impact

Up to 1,150,000 ordinary shares may be issued under the ESPP over its ten-year term, representing approximately 0.98% of the 116,903,979 shares eligible to vote. No material near-term dilution.

dilution

Risk Factors

  • Potential dilution of up to 1,150,000 shares over the ten-year ESPP term, though likely immaterial relative to total shares outstanding.
  • Shareholder opposition to share issuance authorization (26.8M against) and pre-emption rights limitation (28.5M against) indicates some governance concern, though both proposals passed comfortably.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-254615
Document: nams-20260602.htm0001193125-26-254615
Document: 0001193125-26-254615-index-headers.html0001193125-26-254615
Document: 0001193125-26-254615-index.html0001193125-26-254615
Document: 0001193125-26-254615.txt0001193125-26-254615

Track record

3 reports on NAMSW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jun 3, 202623w ago 8-K Neutral 3/10 Viewing Entry $24.90 to $16.51 Now $9.49 −61.88% ▼ −33.68% −36.18% vs SPY
  2. May 7, 202627w ago 8-K Bullish 6/10 Entry $22.80 to $15.00 Now $9.49 −58.38% ▼ −34.21% −38.04% vs SPY
  3. Apr 24, 202629w ago 8-K Neutral 3/10 Entry $19.10 to $19.38 Now $9.49 −50.31% ▲ +1.47% −3.31% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens in 8h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026